Zydus Lifesciences Recalls 70,776 Vials of Hydrocortisone
The pharmaceutical company is pulling the injectable glucocorticoid following failed impurity specifications.
Updated on Oct. 22, 2026 in Healthcare
Live Poll
Does news of frequent drug recalls make you less confident in the safety of your medication?
On October 1, 2026, Zydus Lifesciences initiated a voluntary recall of 70,776 vials of Hydrocortisone Sodium Succinate across the United States. The injectable drug failed to meet established impurity and degradation standards.
Why it matters
As a voluntary safety measure, the recall aims to remove potentially compromised medication from the supply chain after internal testing identified quality concerns. The FDA has categorized this action as a Class II recall, which applies to products that may cause temporary or reversible adverse health consequences.
The recall involves 70,776 vials of the injectable medication manufactured at a facility in Vadodara, India. This regulatory action follows the product's failure to adhere to strict impurity and degradation specifications.
The players
Zydus Lifesciences
This is a global pharmaceutical company headquartered in India that develops, manufactures, and markets a broad portfolio of generic and specialty medications.
FDA
The Food and Drug Administration is the United States federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.
The details
The affected Hydrocortisone Sodium Succinate, a glucocorticoid used for various inflammatory and immune-mediated conditions, was produced in India before shipment to the U.S. market. The company is managing the removal of these specific batches to ensure compliance with federal safety regulations.
Timeline
The voluntary recall action was officially initiated on October 1, 2026.
Market Landscape
This recall aligns with the FDA's Class II recall classification, which dictates the severity and oversight required for pharmaceutical products failing quality standards. Such recalls serve as a standard corrective mechanism within the global manufacturing supply chain to protect public health.
Patients and healthcare providers should verify their medication inventory against the recalled batch numbers to identify affected products. Pharmacists and medical facilities in the United States are expected to coordinate with the company to return the vials and prevent further use.
The takeaway
Voluntary recalls are a standard industry practice used to mitigate risks when products deviate from manufacturing quality standards. Patients concerned about the medications they are currently using should consult with their healthcare provider to discuss alternative treatment options.
Further reading
For broader trends in medical safety and industry regulation, visit the Healthcare section.
Source note: This article includes information reported by ETPharma.
Live Poll
Does news of frequent drug recalls make you less confident in the safety of your medication?
